Cancer Chemotherapy and Pharmacology

, Volume 25, Issue 2, pp 131–134 | Cite as

Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer

  • D. J. TH. Wagener
  • Q. G. C. M. van Hoesel
  • S. H. Yap
  • W. J. Hoogenraad
  • Th. Wobbes
  • S. P. Strijk
5-Fluorouracil, Adriamycin, Cisplatin, Radiation, Pancreatic Cancer

Summary

A total of 19 patients (7 men, 12 women) with locally advanced pancreatic adenocarcinoma were treated with six cycles of FAP (5-fluorouracil, 300 mg/m2 i. v. on days 1–5; Adriamycin, 50 mg/m2 i. v. on day 1; cisplatin, 20 mg/m2 i. v. on days 1–5). Each course was repeated every 28 days. After six cycles, the treatment was followed by irradiation amounting to 4,000 cGy (split course) in combination with 5-FU (500 mg/m2) on days 1–3 of the two irradiation periods. The median age of our patients was 55 years (range, 40–64 years). The median WHO performance status was 1, with a range of 0–2. Three (16%) complete (CR) and six (31%) partial responses (PR) were observed, as were six cases of stable disease (SD) and four of progressive disease (PD). The median duration of response was 11 months, with a range of 4–24 months, and the median survival was 14 months (range, 5–27 + months). FAP toxicity was tolerated fairly poorly. The dose-limiting toxic effect was myelosuppression, with a mean WBC nadir of WHO grade 1.6 (range, 0–3) and a mean platelet count of WHO grade 1.1 (range, 0–4). Nausea and vomiting were not dose-limiting. Complete alopecia was seen in 14/19 patients. Neuropathy was mild (WHO grade 1) in seven and moderate (grade 2) in four. Irradiation in combination with 5-FU was generally well tolerated. Due to several reasons, only ten patients could be treated with all six cycles of FAP. We conclude that in future combined modality studies, irradiation should be given after three cycles of chemotherapy, and that combined modality treatment for locally advanced pancreatic cancer is feasible and warrants further testing.

Keywords

Adenocarcinoma Pancreatic Cancer Neuropathy Partial Response Stable Disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Castro JR, Quivey JM, Lyman JT, Chen GTY, Philips TL, Tobias CA, Alpen EL (1980) Current status of clinical particle radiotherapy at Lawrence Berkeley Laboratory. Cancer 46: 633Google Scholar
  2. 2.
    Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061Google Scholar
  3. 3.
    Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751Google Scholar
  4. 4.
    Gisselbrecht C, Smith FP, Woolley PV, Marty M, Smith L, Lagarde C, Boiron M, Ayoob M, Schein PS (1981) Phase II trial of FAP (5-fluorouracil, Adriamycin, andcis-diamminedichloroplatinum) chemotherapy for advanced measurable pancreatic cancer and adenocarcinoma of unknown primary origin. Proc Am Soc Clin Oncol 1: 454Google Scholar
  5. 5.
    Gudjonsson B (1987) Cancer of the pancreas: 50 years of surgery. Cancer 60: 2284Google Scholar
  6. 6.
    Kaul R, Cohen L, Hendrickson F, Awscholonn M, Hiegsa AF, Rosenberg I (1981) Pancreatic carcinoma: results with fast neutron therapy. Int J Radiat Oncol Biol Phys 7: 173Google Scholar
  7. 7.
    Moertel CG, Frytak S, Hahn RG, O'Conell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5 fluorouracil), and high dose radiation + 5 fluorouracil (Gastrointestinal Tumor Study Group). Cancer 48: 1705Google Scholar
  8. 8.
    Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS (1986) A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053Google Scholar
  9. 9.
    Mohiuddin M, Cantor RJ, Biermann W, Weiss SM, Barbot D, Rosato FE (1988) Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 14: 79Google Scholar
  10. 10.
    Newall J, Wernz J, Gouge T, Muggia F (1982) Locally inoperable pancreatic cancer: a combined modality protocoltoxicity and survival. Proc Am Soc Clin Oncol 1: 97Google Scholar
  11. 11.
    O'Connell MJ (1985) Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3: 1032Google Scholar
  12. 12.
    Schein PS, Smith FP, Dritschillo A, Stablein DC, Ahlgren JD (1983) Phase I–II trial of combined modality FAM (5-fluorouracil, Adriamycin, and mitomycin-C) plus split course radiation (FAM-RT-FAM) for locally advanced gastric and pancreatic cancer: a Mid-Atlantic Oncology Program study. Proc Am Soc Clin Oncol 2: 126Google Scholar
  13. 13.
    Shipley WU, Nardi GL, Cohen AM, Ling CC (1980) Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma. Cancer 45: 709Google Scholar
  14. 14.
    Silverberg E (1978) NCI 3rd National Cancer Survey. Department of Epidemiology and Statistics, American Cancer Society, New YorkGoogle Scholar
  15. 15.
    Sindelar WF, Kinsella TJ, Mayer RJ (1985) Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. Lippincott, Philadelphia p 691Google Scholar
  16. 16.
    Smith FP, Stablein DM, Schein PS (1984) Phase II combination chemotherapy trials in advanced measurable pancreatic cancer. Proc Am Soc Clin Oncol 3: 150Google Scholar
  17. 17.
    Wagener DJTH, Yap SH, Wobbes T, Burghouts JTM, Dam FE van, Hillen HFP, Hoogendoorn GJ, Scheerder H, Vegt SGL van der (1985) Phase II trial of 5-fluorouracil, Adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86Google Scholar
  18. 18.
    Whittington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, Biermann WA, Weiss SM, Pajak TF (1984) Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54: 1991Google Scholar
  19. 19.
    WHO (1979) Handbook for reporting results of cancer treatment (Offset publication 48). WHO, GenevaGoogle Scholar
  20. 20.
    WHO (1979) Handbook for reporting results of cancer treatment (Offset publication 48). WHO, GenevaGoogle Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • D. J. TH. Wagener
    • 1
  • Q. G. C. M. van Hoesel
    • 1
  • S. H. Yap
    • 2
  • W. J. Hoogenraad
    • 3
  • Th. Wobbes
    • 4
  • S. P. Strijk
    • 5
  1. 1.Division of Medical OncologyNijmegen University HospitalNijmegenThe Netherlands
  2. 2.Division of Gastro-enterologyNijmegen University HospitalThe Netherlands
  3. 3.Department of RadiotherapyNijmegen University HospitalThe Netherlands
  4. 4.Department of General SurgeryNijmegen University HospitalThe Netherlands
  5. 5.Department of Diagnostic RadiologyNijmegen University HospitalThe Netherlands

Personalised recommendations